Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

Journal of Clinical Investigation

Volumn 109, Issue 7, 2002, Pages 863-867

  Danilkovitch Miagkova, Alla ^a   Zbar, Berton ^b  

^a Pharmaceutical Product Development   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; SCATTER FACTOR;

CANCER INVASION; CELL TRANSFORMATION; ENZYME ACTIVITY; ENZYME REGULATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; LIGAND BINDING; MISSENSE MUTATION; ONCOGENE; ONCOGENE MET; POINT MUTATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROCESSING; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036221263     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215418     Document Type: Review

References (35)

1. Molecular cloning of a new transforming gene from a chemically transformed human cell line
2. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product
3. Invasive growth: From development to metastasis
4. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
5. Novel mutations of the MET proto-oncogene in papillary renal carcinomas
6. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family
7. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas
8. A novel germ line juxtamembrane Met mutation in human gastric cancer
9. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
10. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression
11. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit
12. Evidence for non-covalent clusters of the c-met proto-oncogene product
13. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase
14. Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor)
15. Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell5 density and is regulated by a cytosolic tyrosine phosphatase activity
16. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met)
17. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors
18. Integrins in invasive growth
19. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor
20. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice
21. Cross-talk between CD44 and c-Met in B cells
22. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met
23. Cross-talk between the proto-oncogenes Met and Ron
24. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells
25. Enhanced transformation by a plasma membrane-associated met oncoprotein: Activation of a phosphoinositide 3′-kinase-dependent autocrine loop involving hyaluronic acid and CD44
26. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor
27. Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes
28. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors
29. Activating mutations for the met tyrosine kinase receptor in human cancer
30. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth
31. Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src
32. The cadherin-catenin adhesion system in signaling and cancer
33. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the β-catenin pathway
34. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: Modeling studies
35. Different point mutations in the met oncogene elicit distinct biological properties